BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36128485)

  • 1. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: CON.
    Kanduri SR; Velez JCQ
    Kidney360; 2022 May; 3(5):803-805. PubMed ID: 36128485
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: PRO.
    Herrmann SM
    Kidney360; 2022 May; 3(5):799-802. PubMed ID: 36128487
    [No Abstract]   [Full Text] [Related]  

  • 3. AKI in Patients Receiving Immune Checkpoint Inhibitors.
    Perazella MA; Sprangers B
    Clin J Am Soc Nephrol; 2019 Jul; 14(7):1077-1079. PubMed ID: 31048326
    [No Abstract]   [Full Text] [Related]  

  • 4. Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.
    Saiki R; Katayama K; Saiki H; Fukumori A; Tsujimoto K; Yamawaki M; Tanaka F; Takahashi D; Oda K; Suzuki Y; Murata T; Dohi K
    BMC Nephrol; 2024 Feb; 25(1):51. PubMed ID: 38336610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY.
    Shirali AC
    Kidney360; 2022 May; 3(5):806-808. PubMed ID: 36129422
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
    Sise ME; Seethapathy H; Reynolds KL
    Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitor-Associated AKI: Debates in Diagnosis, Management, and Rechallenge.
    Seethapathy H; Herrmann SM; Rashidi A
    Semin Nephrol; 2022 Nov; 42(6):151346. PubMed ID: 37137187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
    Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
    Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CON.
    Gutgarts V; Glezerman IG
    Kidney360; 2020 Mar; 1(3):162-165. PubMed ID: 35368625
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
    Perazella MA; Shirali AC
    Kidney Int; 2020 Jan; 97(1):62-74. PubMed ID: 31685311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020.
    Gupta S; Cortazar FB; Riella LV; Leaf DE
    Kidney360; 2020 Feb; 1(2):130-140. PubMed ID: 35372904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
    Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
    Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term steroid therapy for immune-checkpoint-inhibitor-related acute kidney injury.
    Tanemoto M; Iida Y; Kasai T
    Int Urol Nephrol; 2024 Mar; 56(3):1199-1200. PubMed ID: 37646970
    [No Abstract]   [Full Text] [Related]  

  • 16. Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary.
    Perazella MA
    Kidney360; 2020 Mar; 1(3):166-168. PubMed ID: 35378019
    [No Abstract]   [Full Text] [Related]  

  • 17. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
    Azari AE; Stratton R; Singh A
    Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
    [No Abstract]   [Full Text] [Related]  

  • 20. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis.
    Manohar S; Kompotiatis P; Thongprayoon C; Cheungpasitporn W; Herrmann J; Herrmann SM
    Nephrol Dial Transplant; 2019 Jan; 34(1):108-117. PubMed ID: 29762725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.